WPRIM Management System> DCMS> Chinese Journal of Nuclear Medicine and Molecular Imaging> > 42

Volume: 42

1. Application value of delay-phase 99Tc m-PYP scintigraphy and SPECT imaging for diagnosis of transthyretin-related cardiac amyloidosis Page:1—6
2. Predictive value of psTg on the excellent response to 131I treatment in patients with functional lymph node metastases after papillary thyroid carcinoma surgery Page:7—11
3. Localization of epileptic foci in intractable epilepsy induced by hippocampal sclerosis by 11C-choline PET/CT dynamic brain imaging Page:12—16
4. Predictive value of 18F-FDG PET/CT for anti-MDA5 antibody and prognosis of dermatomyositis Page:17—21
5. Automatic diagnosis and assessment of bone metastases on bone scans based on deep learning Page:22—26
6. Analysis of the short-term efficacy of 125I seed implantation for recurrent cervical metastatic lymph nodes of esophageal squamous cell carcinoma after external beam radiation therapy Page:27—30
7. Automatic synthesis and in vivo imaging of Al 18F-NOTA-FAPI-04 Page:31—35
8. Total-body PET/CT current research and future perspectives Page:41—43
9. Progress of molecular imaging in multiple myeloma Page:44—47
10. Application of prostate health index in the diagnosis and treatment of early prostate cancer Page:48—51
11. Preclinical evaluation of 89Zr labeled Daratumumab for imaging diagnosis of multiple myeloma Page:68—73
12. Pretargeted immunoPET imaging with epidermal growth factor receptor monoclonal antibody in mouse models Page:74—79
13. SPECT/CT imaging of PD-L1 expression in non-small cell lung cancer based on 99Tc m labeled anti-PD-L1 nanoantibodies Page:80—83
14. Recombinant human thyroid-stimulating hormone for post-operative assessment in patients with low- to intermediate-risk differentiated thyroid cancer: results of phase Ⅰ study Page:84—89
15. Clinical significance of telomerase reverse transcriptase promoter mutation in radioactive iodine refractory papillary thyroid cancer Page:90—95
16. Prediction of pathological complete response to neoadjuvant chemotherapy in breast cancer using 99Tc m-3PRGD 2 imaging in comparison to 18F-FDG imaging Page:96—103
17. Recent advancement of clinical immunoPET imaging in tumor diagnosis and therapy Page:113—117
18. 18F-FDG PET/CT in detecting immune-related adverse events Page:118—121
19. Methodological study on atrial 18F-FDG PET/CT imaging and preliminary application in atrial fibrillation Page:129—133
20. Application of 18F-FDG PET/CT metabolic parameters in the prediction of perineural invasion in non-metastatic rectal cancer Page:134—138
21. Clinical value of 18F-FDG PET/CT imaging in non-functional pancreatic neuroendocrine neoplasms Page:139—143
22. Prognostic value of pretreatment 18F-FDG PET/CT in patients with primary malignant melanoma Page:144—148
23. Clinical value of quantitative 99Tc m-HYNIC-PSMA SPECT/CT in the diagnosis of prostate cancer Page:149—153
24. Assessment of left ventricular diastolic dyssynchrony and its influencing factors early after acute myocardial infarction by SPECT gated myocardial perfusion imaging: an experimental study Page:154—159
25. Establishment and performance evaluation of Der p 1/Der p 2 specific immunoglobulin E detection for the components of dust mite allergens based on chemiluminescence immunoassay Page:160—164
26. 2021 Radiological Society of North America annual meeting: molecular nuclear medicine Page:177—180
27. Potential regulatory mechanisms of thyroid iodine metabolism by gut microbiota Page:181—185
28. Prognostic value of pretreatment 18F-FDG PET/CT metabolic parameters in elderly classical Hodgkin′s lymphoma Page:196—201
29. Value of 18F-FDG PET/CT in the interim therapeutic and prognostic evaluation of primary gastrointestinal lymphoma Page:202—208
30. Relationship between 18F-FDG PET/CT Lugano lymphoma response evaluation criteria and prognosis at the end of chemotherapy for diffuse large B-cell lymphoma Page:209—215
31. Clinical study on the 18F-FDG PET/CT " one-stop" evaluation of the volume and activity of epicardial adipose tissue Page:216—220
32. Preliminary exploration of the relationship between the serum anti-Müllerian hormone and the related clinical factors Page:221—225
33. Time-resolved fluorescence immunochromatographic assay for the detection of mycoplasma pneumoniae IgM and IgG Page:226—230
34. Preparation of N- 18F-fluoroethyl-tofacitinib and its application in the imaging of rheumatoid arthritis Page:231—236
35. Application and progress of radiomics in tumor PET imaging Page:240—242
36. Advances in the application of nuclear medicine imaging in the diagnosis and treatment of systematic light chain amyloidosis Page:243—247
37. Correlation analysis between SUV index in 18F-FDG PET/CT imaging and invasiveness of early lung adenocarcinoma Page:257—262
38. Clinical application of 18F-FDG PET/CT parameters in predicting tumor spread through air spaces in patients with lung adenocarcinomas at T1-2 stage Page:263—268
39. Differential diagnostic value of 18F-FDG PET/CT in multiple myeloma and unknown osteolytic metastasis Page:269—273
40. Imaging features of 99Tc m-dextran lymphoscitigraphy in thoracic duct exports obstruction Page:274—278
41. Primary study of motion correction effect on myocardial blood flow quantitative imaging with CZT SPECT Page:279—283
42. Serially evaluation of changes in myocardial perfusion, hibernation myocardium and left ventricular function in the development of chronic coronary artery occlusion by gated SPECT perfusion and gated PET imaging in pigs Page:284—288
43. Preliminary study on 99Tc m-3PRGD 2 imaging to verify the anti-angiogenesis mechanism and efficacy of Mongolian medicine Sendeng-4 decoction for rheumatoid arthritis Page:289—293
44. Research progress and the potential imaging applications in supra-normal left ventricular ejection fraction Page:303—307
45. Application of molecular imaging in chimeric antigen receptor T cell therapy Page:308—312
46. Preparation of no-carrier-added 161Tb by lanthanide resin Page:325—329
47. Preparation and use of the 225Ac- 213Bi generator Page:330—334
48. Study on the relation of the radiochemical purity and in vivo imaging effect of 68Ga-DOTATATE injection Page:335—339
49. Research on medical radioisotope production technology by medium and high-energy cyclotron and solid target Page:340—346
50. Prognostic role of baseline 18F-FDG PET/CT metabolic parameters and relevant clinical factors in peripheral T-cell lymphoma, not otherwise specified Page:347—351
51. Clinical value of 18F-FDG PET/CT imaging for detecting immune related adverse events of the combined immunotherapy in hepatobiliary carcinoma Page:352—356
52. Comparison of IQ-SPECT and low energy high-resolution collimator SPECT in clinical application Page:357—362
53. Targeting TSHR and ICAM-1 for treatment of Graves′ disease in BALB/c mice Page:363—367
54. Application and prospect of the MOOC of Nuclear Medicine resource in teaching for undergraduates Page:374—377
55. Construction and validation of the predictive models for the pathological invasion of early lung adenocarcinoma presenting as ground glass nodules based on 18F-FDG PET/CT Page:385—390
56. Multimodal study on cerebral functional imaging under sleep deprivation Page:391—396
57. Diagnostic value of 18F-FDG PET/CT for Richter syndrome of chronic lymphocytic leukemia Page:397—400
58. Effect of different β values combined with partial volume effect correction on the semi-quantitative accuracy and image quality of 68Ga-PSMA PET/CT Page:401—405
59. Targeted therapy of Apt-siRNA combining with docetaxel for PSMA-positive prostate cancer and monitoring imaging of 99Tc m-Apt-siRNA Page:406—411
60. Effect of different glucose concentrations on the uptake of 18F-FDG in non-small cell lung cancer Page:412—415
61. Mechanism and research progress of cancer treatment by α-therapy combined with immunotherapy Page:424—427
62. Clinical research progress on radiopharmaceuticals imaging targeting epidermal growth factor receptor Page:428—432
63. Research progress on health-related quality of life in patients with thyroid cancer Page:432—435
64. Prognostic value of 18F-FDG PET/CT imaging of inflammation in evaluating left ventricle function in patients with acute myocardial infarction Page:452—456
65. Value of 18F-FDG PET/CT in evaluating the activity of Takayasu arteritis Page:457—461
66. Value of 18F-FDG total-body PET/CT 2-hour imaging in detection of Takayasu arteritis Page:462—466
67. Diagnostic value of myocardial blood flow quantitative imaging with CZT SPECT in patients with high-risk coronary artery disease Page:467—472
68. Application of radionuclide renal dynamic imaging combined with double plasma method in evaluation of split renal glomerular filtration rates pre- and post-interventional treatment in patients with unilateral hydronephrosis Page:473—477
69. Automatic synthesis of 18F-AlF-NOTA-octreotide and PET/CT imaging in neuroendocrine tumor Page:478—481
70. 68Ga-DOTA-VAP molecular probe targeted glucose-regulated protein 78 for specific microPET/CT imaging of tumors Page:482—486
71. External quality assessment results of in vitro analysis of nuclear medicine from 2004 to 2018 in Shanghai Page:487—490
72. Application advances of multiparametric PET/MR imaging in breast cancer Page:494—498
73. Advances in molecular imaging by targeting macrophages of atherosclerosis vulnerable plaques Page:499—503
74. Characteristics of brain glucose metabolism in patients with anti- N-methyl- D-aspartate receptor encephalitis underlying different inducing factors Page:513—517
75. Value of 18F-FDG uptake features in differential diagnosis of benign and malignant solitary pulmonary lesions Page:518—523
76. Analysis and evaluation of 18F-FDG PET/CT imaging in primary breast diffuse large B cell lymphoma Page:524—528
77. External exposure dose of 177Lu-PSMA-617 to the public in the treatment of prostate cancer Page:529—533
78. Establishment of biological reference interval for reverse triiodothyronine by indirect method Page:534—537
79. Automatic synthesis of 18F-fallypride and evaluation of microPET/CT imaging effect Page:538—541
80. Ultrasmall nanoprobe in MR/CT bimodal imaging for tumor angiogenesis Page:542—546
81. Study of PET automatic drug infusion system for radiation protection and precision injection in nuclear medicine nursing Page:547—549
82. Quality control of the multi-centre clinical trial on PET/CT brain imaging Page:550—555
83. Clinical advances of 18F-FDG PET/CT in evaluating differentiation of recurrent or metastatic differentiated thyroid cancer and guiding 131I therapy Page:559—562
84. Applications of stable isotope metabolic flux analysis in tumor metabolic reprogramming Page:563—567
85. Establishment and validation of a nomogram model for predicting EGFR mutations in lung adenocarcinoma Page:577—582
86. Application of combining 18F-FDG PET imaging and radiomics in the diagnosis of Parkinson′s disease and atypical parkinsonian syndromes Page:583—587
87. Value of 18F-FDG PET/CT in the differential diagnosis of nasopharyngeal carcinoma and nasopharyngeal lymphoma Page:588—592
88. Effect of dietary intake before fasting on physiological distribution of 18F-FDG PET/CT imaging Page:593—596
89. Comparison of preparation for 177Lu-labeled radiopharmaceutical and its preliminary clinical application Page:597—601
90. Preparation of Al 18F-PSMA-11 and its preliminary PET/CT imaging Page:602—606
91. SPECT/CT imaging of tumor-infiltrating CD8 + T cell to predict the efficacy of anti-PD-1 immunotherapy in mice Page:607—612
92. Guidance for operation and reading of 18F-FDG PET brain imaging in dementia Page:613—618
93. Advances in the somatostatin receptor-targeting imaging and peptide receptor radionuclide therapy for pheochromocytomas and paragangliomas Page:623—627
94. Research progress of salivary glands injury secondary to 225Ac/ 177Lu-PSMA-617 in the treatment of prostate cancer and its protection Page:628—632
95. Serologically biochemical evaluation for patients with locally advanced/metastatic radioactive iodine-refractory differentiated thyroid cancer treated by apatinib Page:644—649
96. Preliminary study of apatinib combined with 131I therapy in patients with progressive metastatic differentiated thyroid cancer Page:650—655
97. Short-term effect of targeted drugs on quality of life in patients with radioactive iodine-refractory differentiated thyroid cancer Page:656—660
98. Study of altered brain metabolism and connectivity in temporal lobe epilepsy Page:661—665
99. Efficacy and prognostic factors analysis of CT-guided 125I seeds implantation for primary hepatocellular carcinoma Page:666—671
100. Automatic synthesis and myocardial imaging of 11C-meta-hydroxyephedrine Page:672—675
101. Preparation and microPET imaging of extradomain-B fibronectin specific probe 18F-AlF-NOTA-PEG 4-ZD2 Page:676—680
102. Research progress in thyroid cancer: dedifferentiation mechanisms and differentiation therapies Page:686—691
103. Research progress of peptide receptor radionuclide therapy combined with other drugs in the treatment of neuroendocrine tumors Page:692—695
104. Study on improving the quality of low-dose PET images of children based on generative adversarial networks Page:708—712
105. Evaluation on the feasibility of total-body PET/CT imaging with short acquisition time in lungs and parenchymal organs Page:713—718
106. Kinetic metrics changes of FDG in key organs after chemo-immunotherapy in patients with locally advanced non-small cell lung cancer identified by total-body PET/CT dynamic imaging Page:719—723
107. Added value of 18F-FDG total-body PET/CT dynamic imaging in the diagnosis of liver malignant tumors Page:724—728
108. Kinetic metrics of 68Ga-FAPI-04 in patients with pancreatic cancer identified by total-body PET/CT dynamic imaging Page:729—733
109. Diagnostic values of different diagnostic criteria of 18F-DCFPyL PET/CT for primary prostate cancer Page:734—738
110. Efficacy of radiotherapy in MDA-MB-231 breast cancer bearing nude mice evaluated by 18F-FDG total-body PET/CT dynamic imaging Page:739—743
111. Site-specific labelling and biological evaluation of PD-L1 targeted single-domain antibody Page:744—750
112. Application of artificial intelligence in PET/CT for the therapy prediction and prognosis evaluation of malignant tumors Page:754—758

©2019 - Present World Health Organization Regional Office for the Western Pacific. All Rights Reserved.